Advanced Solid Tumors
Imcheck Therapeutics focuses on advanced-stage and relapsed/refractory cancer, with clinical interest in treatment-resistant disease across multiple solid tumor settings.
- Metastatic colorectal cancer
- Metastatic ovarian cancer
- Metastatic pancreatic ductal adenocarcinoma
The sponsor’s oncology portfolio includes tumors with limited treatment options, reflecting a strong emphasis on difficult-to-treat metastatic disease.
Melanoma
Clinical activity also includes metastatic or unresectable refractory melanoma, with attention to patients whose disease has progressed despite prior therapy.
- Advanced melanoma
- Unresectable disease
- Refractory disease
This area places melanoma within the sponsor’s broader interest in immune-responsive solid tumors.
Hematologic Malignancies
Imcheck Therapeutics is also involved in research for hematologic malignancies, including acute myeloid leukemia and other relapsed or refractory blood cancers.
- Acute myeloid leukemia
- Relapsed/refractory hematologic cancer
- Advanced blood malignancies
These studies extend the sponsor’s oncology interests beyond solid tumors into aggressive systemic cancers.
Immuno-Oncology
The sponsor’s research spans immuno-oncology approaches in both solid and hematologic cancers, with interest in immune-based combination strategies.
- Checkpoint inhibitor combinations
- Interleukin-2
- Venetoclax
- Azacitidine
These therapeutic areas align with efforts to address tumor resistance through immune-directed cancer treatment.
